- 研究领域
- 技术
- 仪器平台
- 试剂和服务
- 生物信息学
- 科学内容
- ILLUMINA公司
- 支持
TruSight Tumor 170, a next-generation sequencing assay designed to cover 170 genes associated with common solid tumors, is an enrichment-based targeted panel that simultaneously analyzes DNA and RNA, covering a wide range of genes and variant types. The comprehensive nature provides laboratories with a deep view into the genetics of cancer.
| 仪器 | 推荐的样本数 | 读长 |
|---|---|---|
| NextSeq 550 System | 每次运行的样本（高通量）：16（8个DNA样本和8个RNA样本），10（DNA样本），16（RNA样本） | 2 × 101 bp (最大推荐值) |
| HiSeq 2500 System | 每次运行的样本（快速运行）：12（6个DNA样本和6个RNA样本），6（DNA样本），12（RNA样本） | 2 × 101 bp (最大推荐值) |
| TruSight Tumor 170 | TruSight Tumor 15 | TruSight Oncology 500 | |
|---|---|---|---|
| 变异种类 | 基因融合, 插入缺失, 单核苷酸多态性（SNP）, 结构变异, 拷贝数变异（CNV）, 体细胞变异 | 体细胞变异, 插入缺失 | 插入缺失, 体细胞变异, 单核苷酸多态性（SNP）, 基因融合 |
| 技术 | 测序 | 测序 | 测序 |
| 方法 | 靶向RNA测序 , 靶向DNA测序 | 扩增子测序 , 靶向DNA测序 | 靶向RNA测序 , 靶向DNA测序 , 免疫测序 |
| 核酸类型 | RNA, DNA | DNA | RNA, DNA |
| 物种类别 | 人类 | 人类 | 人类 |
| 特殊的样本类型 | 低起始量样本, FFPE组织 | FFPE组织 | FFPE组织 |
| 癌症类型 | 实体瘤 | 实体瘤 | 泛癌 |
| 系统兼容性 | NextSeq 550 , NextSeq 500 , HiSeq 2500 | MiniSeq , 研究模式下的MiSeqDx , MiSeq , MiSeq | NextSeq 500 , NextSeq 550 |
Results of analysis indicate that TruSight Tumor 170, with comprehensive coverage of cancer-related genes, shows high concordance with whole exome sequencing for accurate assessment of tumor mutational burden.
Standard extractions from FFPE embedded samples provide sufficient material (40ng) in >95% of samples that were extracted by Illumina. This data shows that the TruSight Tumor 170 panel is a robust assay that generates passing sample QC data in >85% of samples with varying quality, and in >95% of samples that have quality metrics that fall within the recommendations for the kit.
TruSight Tumor 170 can achieve high sensitivity and specificity for the detection of somatic variants (small variants and CNVs) from DNA extracted from FFPE tissues.
Through examining limit of detection in the context of RNA expression, this study shows that TruSight Tumor 170 provides high sensitivity and specificity in RNA variant calling down to 5 copies of transcript per ng of input.
Rare Variant Detection with the TruSight UMI Toolkit
Technical Note | PDF< 1 MB
Application Note | PDF2 MB
Assessing DNA and RNA Quality from FFPE Samples for TruSight Tumor 170
White Paper | PDF< 1 MB
Data Sheet | PDF1 MB
product_file | EXCEL< 1 MB
Targeting 1385 cancer genes for gene expression, variant, and fusion detection studies in many RNA sample types including blood, bone marrow, and formalin-fixed, paraffin-embedded (FFPE) tissue.
Provides comprehensive gene fusion detection in formalin-fixed, paraffin-embedded (FFPE) and other cancer research samples.